NTUS Natus Medical Incorporated

The supporting community of Otoscan® expands its global influence

The supporting community of Otoscan® expands its global influence

Another key partner joins the Otocloud community, expanding the reach even further.

ReSound is officially accepting Otoscan files!

PLEASANTON, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, is pleased to announce a collaboration with ReSound, the global leader in smart hearing aid solutions, aiming at providing exceptional hearing care solutions to hearing aid users around the globe.

“Having another key player join the Otocloud community is very important to us and our customers, and it further expands the reach of Otoscan and supports our quest to make Otoscan the best practice solution for digital scanning of the ear. We listened to our customers and their desire for a better overall patient experience,” says Austin Noll, Executive Vice President and Chief Commercial Officer at Natus. “By providing a digital scanning solution that the patient can see, patients feel more informed when selecting which product is right for them.”

This collaboration combines the best of both worlds in the field of audiology: advanced scanning technology offered by the Otoscan and high-quality hearing aid products manufactured by ReSound, a pioneer in the hearing aid industry. The ordering process is streamlined, and files are shared through Otocloud™, a web-based cloud service.

Developed by hearing care professionals for hearing care professionals

Otoscan is designed specifically for the needs of audiologists and hearing aid dispensers selling and fitting custom hearing aids. Otoscan enables hearing care professionals to make digital impressions for custom in-the-ear pieces such as earmolds and hearing aids. The scanner solution applies state of the art technology to transform images of the ear into 3D digital files that are then securely uploaded to Otocloud™ for immediate use in production of custom products, delivering significant efficiency and quality-gains in the production of hearing aids compared to other existing approaches.

Otoscan is commercially available in the United States, United Kingdom, Germany, France, Spain, Italy, Denmark, the Netherlands, Belgium, Austria, Switzerland, Australia, New Zealand, Japan, Hong Kong and Canada.

For more information about Otoscan, please visit .

About ReSound

ReSound hearing aids, available from leading hearing care professionals, have set worldwide standards for quality and intuitive technology. ReSound was the first hearing aid brand to be compatible with the iPhone and pioneered the development of 2.4 GHz wireless technology. Continuing to lead in connectivity, ReSound collaborated with Google and Cochlear to develop the world’s first direct Audio Streaming for Hearing Aids (ASHA) using state-of-the-art Bluetooth® Low Energy. This world’s first allows people to use their hearing devices like a headset to enjoy music, take calls and much more, while using a protocol designed to maximize battery life when streaming.

About GN Group

The GN Group is a global leader in intelligent hearing, audio and video collaboration solutions that let you hear more, do more and be more than you ever thought possible. Its pioneering 150-year journey has taken it from telegraph cables to radio waves and intelligent audio engineering. With its unique competencies in medical, professional and consumer audio solutions, GN strives to meet individual customer needs and transform lives through the power of sound.  

GN was founded with a truly innovative and global mindset. Today, it honors that legacy with world-leading expertise in the human ear, sound, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, FalCom and BlueParrott in 100 countries. Founded in 1869, the GN Group employs 6,000 people and is listed on Nasdaq Copenhagen (GN.CO).

About Natus Medical Incorporated

Natus is a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages.

Additional information about Natus Medical Incorporated can be found at .

Natus, Otocloud, and Otoscan are trademarks of Natus Medical Incorporated.  All other trademarks are the property of their respective owners.

Natus Medical Incorporated

Drew Davies

Executive Vice President and Chief Financial Officer

(925) 223-6700

EN
24/02/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Natus Medical Incorporated

 PRESS RELEASE

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 ...

ArchiMed completes acquisition of Natus Medical Incorporated for $1.2 billion total equity value MIDDLETON, Wis., July 21, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announced today that the MED Platform II fund of ArchiMed (“ArchiMed”), a leading investment firm focused exclusively on the healthcare industry, completed the acquisition of Natus. In accordance with the definitive ...

 PRESS RELEASE

Natus Medical Announces First Quarter 2022 Financial Results

Natus Medical Announces First Quarter 2022 Financial Results  Q1-2022 Key ResultsRevenue (millions)$119.8 • Total revenue increased 4.2% compared to Q1 2021• Generated $8.9 million in operating cash flowGAAP EPS$0.06 Non-GAAP EPS$0.22     MIDDLETON, Wis., May 05, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, today announced financial results for the three months ended March 31, 2022...

 PRESS RELEASE

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50...

Natus Medical Incorporated to be acquired by ArchiMed Group for $33.50 per share in cash Highlights: •        Transaction values Natus Medical, Incorporated at approximately $1.2 billion total equity value•        Pre-announces preliminary financial results for the first quarter ended March 31, 2022 MIDDLETON, Wis., April 18, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathways, and eight sensory nervous systems, announce...

 PRESS RELEASE

Natus Medical to Hold 2022 First Quarter Financial Results Conference ...

Natus Medical to Hold 2022 First Quarter Financial Results Conference Call on May 6th PLEASANTON, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ: NTUS), (the “Company” or “Natus”), a leading provider of medical device solutions focused on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages, announced today that the Company will release its 2022 first quarter financial results after the close of the market on Thursday, May 5th. Natus management will host a conference call on Friday, May 6th at 8:00 a.m. Eastern...

 PRESS RELEASE

Natus Medical Announces Fourth Quarter 2021 Financial Results

Natus Medical Announces Fourth Quarter 2021 Financial Results  Q4-2021 Key ResultsRevenue (millions)$128.7 • Revenue increased 8% compared to Q4 2020• Revenue increased 14% compared to full year 2020• $12.8 million in operating cash flow for Q4 2021• $63.9 million in operating cash flow for the year 2021GAAP EPS$0.05 Non-GAAP EPS$0.47     PLEASANTON, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:NTUS) (the “Company” or “Natus”), a leading provider of medical device solutions to screen, diagnose, and treat disorders affecting the brain, neural pathw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch